期刊文献+

亲和层析介质性能分析及其在单抗纯化中的应用 被引量:1

Comparison of Protein A Affinity Media for Chromatographic Performance and Purification of Monoclonal Antibodies
原文传递
导出
摘要 对6种商品化蛋白A亲和层析介质进行了性能分析,包括动态载量、洗脱条件等,并对含有单抗药物Mab-HS006的实际料液进行了捕获分离,对宿主细胞蛋白及蛋白A的残留进行了分析。结果表明,Prosep Ultra Plus和Mabselect SuRe亲和介质的载量最高,而Protein A Sepharose CL-4B和r-Protein A Sepharose的洗脱条件最温和。一步层析捕获分离Mab-HS006单抗的结果表明,各种介质的纯度均可达90%以上,Prosep Ultra Plus的宿主细胞蛋白残留最高,Mabselect SuRe蛋白A的脱落最低。 During the selection of protein A the affinity media for the purification of monoclonal antibodies,dynamic binding capacity,elution conditions and purity are essential parameters to be evaluated.In this study,these performances were conducted for six kinds of affinity media.Furthermore,the media were used for purification of monoclonal antibody Mab-HS006 from crude CHO fermentation supernatant.A larger dynamic binding capacity was found for Prosep Ultra Plus and Mabselect SuRe,and a wilder elution condition was found for Protein A Sepharose CL-4B and r-Protein A Sepharose.All the media could achieve a high purity of over 90% and recovery of more than 98%.For the media Prosep Ultra Plus,the highest host cell protein content of eluates was found,whereas for Mabselect SuRe the lowest protein A leakage level was achieved.
出处 《药物生物技术》 CAS CSCD 2012年第1期40-44,共5页 Pharmaceutical Biotechnology
基金 中国博士后科学基金资助项目(20110491826)
关键词 蛋白A亲和层析 动态载量 洗脱行为 单克隆抗体 纯化 Protein A affinity chromatography Dynamic binding capacity Elution conditions Monoclonal antibody Purification
  • 相关文献

参考文献16

  • 1Aggarwal S. What's fueling the biotech engine-2009-2010 [ J]. Nature Biotechnol,2010,28 ( 11 ) : 1165.
  • 2王旻.治疗性抗体药物研究与发展趋势[J].药物生物技术,2011,18(2):95-99. 被引量:9
  • 3Low D, 0' Leary R, Pujar NS. Future of antibody purification [J]. J Chromatogr B,2007,848 ( 1 ) : 48.
  • 4Hober S, Nord K, Linhult M. Protein A chromatography for antibody purification[J]. J Chromatogr B,2007,848( 1 ) : 40.
  • 5Hahn R, Bauerhansl P, Shimahara K,et al. Comparison of protein A affinity sorbents II. Mass transfer properties [J]. J Chromatogr A ,2005,1093(1-2) : 98.
  • 6Swinnen K, Krul A, Van Goidsenhoven I , et al. Performance comparison of protein A affinity resins for the purification of monoclonal antibodies [ J ]. J of chromatogr B, 2007, 848 (1):97.
  • 7Tugcu N, Roush D J, Goklen KE,et al. Maximizing productivity of chromatography steps for purification of monoclonal antibodies [J]. Biotech Bioeng,2008,99 ( 3 ) : 599.
  • 8Griffith C M, Morris J, Robichaud M, et al. Fluidization characteristics of and protein adsorption on fluoride-modified porous zirconium oxide particles [ J]. J Chromatogr A, 1997, 776 (2) : 179.
  • 9Li R, Dowd V, Stewart D, et al. Design, synthesis and application of a protein A mimetic [ J ]. Nat Biotechnol, 1998,16 (2) : 190.
  • 10Subramanyam M. Immunogenicity of biotherapeutics-an overview [J]. J lmmunotoxicol,2006,3 (3) : 151.

二级参考文献36

  • 1Jarvis L. Monoclonal antibody drug marke't poised for explosive growth[M]. New York: Schnell Publishing Compang , Inc. 2002.8.
  • 2Reichert J, Paylou. From the analyst's couch: Monoclonal antibodies market [J]. Nal Rev Drug Discou, 2004, 3 (5):383.
  • 3Louet S. Can China bring its own pipeline to the market[J]. Nat Biotechnl, 2004, 22(12) : 1497.
  • 4JM沃克等编,谭天伟等译.分子生物学与生物技术[M].北京:化学工业出版社,2003.
  • 5Hoogcnboom If. Selecting and screening recombinant antibody libraries [J].Nat Biotechuol, 2005,23(10) : 1105.
  • 6Mazor Y, Van Blarcom T, Mabry R, etal. Isolation of engineered full length antibodies from libraries expressed in Escherichia coil[J].Nat Biotechnol, 2007,25 (5):563.
  • 7Benekli M, Hahn T, Williams BT, et al.Muromonab CD3 (Orthoclone OKT3 ), methylprednisolone and cyclosporine for acute graft - versus - host disease prophylaxis in allogeneic bone marrowtransplantation [J]. Bone Marrow Transplant, 2006,38(5) :365.
  • 8Ebel W, Routhier E, Foley B, et al. Preclinical evaluation of MORAb- 003, a humanized monoclonal antibodyantago nizingfolate receptor - alpha [J]. Cancer Immun, 2007,7 : 6.
  • 9Olsson L, Kaplan H. Human - human hybridomas producing monoclonal antibodies of predefined antigenic specificity [J]. Proc Nail Acad Sci USA ,1980,77:5429.
  • 10Shoenfeld Y. Production of autoantibodies by human human hybridomas [J].Clin Invest, 1982, 20: 205.

共引文献18

同被引文献23

  • 1应国清,王玉姣,易喻,俞志明,石陆娥.免疫亲和层析技术及其医药应用进展[J].药物生物技术,2005,12(5):342-346. 被引量:9
  • 2Hahn R, Bauerhansl P, Shimahara K, et al. Comparison of protein A affinity sorbents Ⅱ. Mass transfer properties [ J ]. J Chroma- togr , 2003 , 790 : 3 5 -51.
  • 3TaoY, Carta G, Ferreira G,et al. Adsorption of deamided antibody variants on macroporous and dextran-grafted cationexchangers: Ⅰ. Adsorption equilibrium [ J ] . J Chromatogr A, 2011,1218: 1519-1529.
  • 4TaoY, Carta G, Ferreira G, et al. Adsorption of deamided antibody variants on macroporous and dextran-grafted cation exchangers: Ⅱ. Adsorption kinetics [ J ]. J Chromatogr A, 2011, 1218: 1530-1540.
  • 5Carta G, UbieraAR, PahstT M. Protein Mass Transfer Kinetics in Ion Exchange Media: Measurements and Interpreyations [ J ]. Chem Eng Technol,2005,28 ( 11 ) : 1252-1264.
  • 6Bergander T, Nilsson-Valimaa K, Oberg K, et al. High-Through Process Development:Determination of Dynamic Binding Capacity Using Microtiter Filter Plates Filled with Chromatography Resin [ J ]. Biotechnol,2008,24:632-639.
  • 7Merson JR. An Assay Tray Assembly [ P ]. USP Patent, 91303083.9,1991.
  • 8KramarczykJK. High-Throughput Screening of Chromatographic Resins and Excipients for Optimizing Selectivity [ C ]. Medford, MA :Tufts University,2003.
  • 9Coffman JL, Kramarczyk JF, Kelly BD. High-Throughput Screen- ing of Chromatographic Separations: I Method Development and Column Modeling [ J ]. Biotechnol and Bioeng, 2008,100 ( 4 ) : 605-618.
  • 10KramarczykJF, Kelley BD, Coffman JL. High-Throughput Screen- ing of Chromatographic Separations: Ⅱ. Hydrophobic Interaction [ J ]. Biotechnol and Bioeng,2008,100 (4) :707-720.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部